These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31344163)

  • 21. [MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].
    Izumi S; Kimura K; Takeda Y; Tsukamoto S; Yamazaki M; Mishina T; Nagai Y; Takaishi K; Nagao Y; Oshima-Hasegawa N; Mitsukawa S; Mimura N; Takeuchi M; Ohwada C; Iseki T; Ota S; Nakaseko C; Sakaida E
    Rinsho Ketsueki; 2018; 59(12):2600-2605. PubMed ID: 30626796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
    Kim JL; Gerrie AS; Savage KJ; Villa D; Scott D; Craig JW; Farinha P; Skinnider B; Slack G; Connors JM; Sehn LH; Venner C; Freeman CL
    Leuk Lymphoma; 2024 Mar; 65(3):346-352. PubMed ID: 38156444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Waldenström Macroglobulinemia in Limited-Resource Settings.
    Riva E; Tietsche de Moraes Hungría V; Chiattone C; Martínez-Cordero H
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):801-807. PubMed ID: 37258356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
    Buske C
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
    Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
    Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Waldenström macroglobulinemia: my way.
    Gertz M
    Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2012 May; 87(5):503-10. PubMed ID: 22508368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
    Ahn A; Park CJ; Cho YU; Jang S; Seo EJ; Lee JH; Yoon DH; Suh C
    Ann Lab Med; 2020 May; 40(3):193-200. PubMed ID: 31858758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
    Tedeschi A; Picardi P; Ferrero S; Benevolo G; Margiotta Casaluci G; Varettoni M; Baratè C; Motta M; Gini G; Goldaniga MC; Visco C; Zaja F; Belsito Petrizi V; Ravelli E; Gentile M; Urbano MA; Franceschetti S; Ghione P; Orsucci L; Frustaci AM; Gaidano G; Vitolo U; Morra E
    Leuk Lymphoma; 2015; 56(9):2637-42. PubMed ID: 25651423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.
    Saito A; Isoda A; Kojima M; Yokohama A; Tsukune Y; Sasaki M; Ito S; Ohtsu A; Koike M; Murayama K; Moriya K; Tamura H; Matsumoto M; Nakahashi H; Tanosaki S; Sakura T; Kawamura T; Miyanaga T; Nakamura N; Murakami H; Handa H; Tsukamoto N
    Int J Hematol; 2017 Nov; 106(5):681-690. PubMed ID: 28687991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Skin abnormalities as first sign of Waldenström macroglobulinaemia].
    Visser MF; Croon-de Boer F; Lonnee ER; Drees A
    Ned Tijdschr Geneeskd; 2010; 154():A2097. PubMed ID: 21029489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2015 Apr; 90(4):346-54. PubMed ID: 25808108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
    Guidez S; Labreuche J; Drumez E; Ysebaert L; Bakala J; Delette C; Hivert B; Protin C; Declercq H; Verlay M; Marolleau JP; Duhamel A; Morel P;
    Blood Adv; 2018 Nov; 2(22):3102-3111. PubMed ID: 30455359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].
    Xiong W; Yi S; Li H; Liu H; Li Z; Lü R; Liu W; Zou D; Qiu L
    Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(44):3593-7. PubMed ID: 26813371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature.
    Delgado J; Canales MA; Garcia B; Alvarez-Ferreira J; Garcia-Grande A; Hernandez-Navarro F
    Am J Hematol; 2002 Feb; 69(2):127-31. PubMed ID: 11835349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2011 May; 86(5):411-6. PubMed ID: 21523800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful Treatment of Bing-Neel Syndrome Accompanying Waldenström's Macroglobulinemia with R-MPV: A Case Report.
    Kikukawa Y; Yamamura-Fujimoto A; Endo S; Miyagawa E; Kawano Y; Ueno S; Mitsuya H; Hata H; Okuno Y
    J Clin Exp Hematop; 2015; 55(2):113-9. PubMed ID: 26490525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Slawik HR; Bückner U; Otremba B; Sauer A; Zahn MO; Wetzel N; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2020 Aug; 38(3):344-352. PubMed ID: 32383192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
    Castillo JJ; Gustine JN; Keezer A; Meid K; Flynn CA; Dubeau TE; Chan G; Chen J; Demos MG; Guerrera ML; Jimenez C; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Xu L; Yang G; Hunter ZR; Treon SP
    Am J Hematol; 2020 Apr; 95(4):372-378. PubMed ID: 31868242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.